Ben Derman: One Recommendation I Make Over and Over is to Use a Prophylactic DOAC Instead of Aspirin
Ben Derman, Asst Professor at University of Chicago, posted on X:
“One recommendation I make over and over is to use a prophylactic DOAC instead of aspirin in newly diagnosed myeloma. Just choose a DOAC [they are getting much more affordable!]!
Risk scores lack validation for choosing VTE ppx.
The BENEFIT trial shows 6-month incidence of VTE was 0.8% in patients receiving ppx DOAC vs 5.6% with ppx heparin, and 9.8% in patients receiving aspirin.”
Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Authors:Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet-Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu

Read full article here.
Stay informed with Hemostasis Today.
-
Oct 19, 2026, 08:20Cory Dugan: The IRONWOMAN Trial Individual Responses to IV Iron Therapy in Active Women
-
Oct 19, 2026, 07:36Johannes Kaesmacher: Cerebral No-Reflow After Thrombectomy Toward a Standardized Definition
-
Oct 19, 2026, 07:33Beth Psaila: Highlights from IACH Annual Meeting and MPN Horizons
-
Oct 19, 2026, 07:29Wolfgang Miesbach: Can Losartan Activate Brown Fat? – Nature Study Explores New Therapeutic Link
-
Oct 19, 2026, 07:22Ruben Mesa: Honored to Speak at the Tandem MPN Meetings of IACH
-
Oct 19, 2026, 07:19Saneha Anjum Shaikh: Parul University Partners with Raktasevak Bike Ride 2026 for Blood Donation Drive
-
Oct 19, 2026, 07:09Alejandro González Veliz: No ST Elevation Does Not Guarantee an Open Coronary Artery
-
Oct 19, 2026, 06:02Thomas Dayspring: Vascular Resilience – What Is It and How Can We Measure It?
-
Oct 19, 2026, 05:53Kevon Dindial: Collaboration for Better Childhood Cancer Outcomes